Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

LSU Health Sciences Center

Neither a doctor nor a teaching hospital

Research payments

$963,001

156 payments

Through program year 2025, LSU Health Sciences Center is reported as receiving $963,001 in research payments, across 156 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $234,358 39
2024 Research $137,758 27
2023 Research $145,628 18
2022 Research $64,463 4
2021 Research $26,145 5
2020 Research $150,772 17
2019 Research $203,877 46

Breakdown

Who paid Research payments · program years 2019–2025
  1. Gilead Sciences, Inc. $509,523 91 payments
  2. Cepheid $137,000 5 payments
  3. Ucb SA $86,715 4 payments
  4. La Jolla Pharmaceutical Company $45,606 5 payments
  5. Bard Peripheral Vascular, Inc. $39,731 5 payments
  6. Tetraphase Pharmaceuticals, Inc. $39,222 16 payments
  7. Bioventus LLC $32,679 1 payment
  8. Genentech, Inc. $25,302 8 payments
  9. Actelion Pharmaceuticals US, Inc. $12,600 6 payments
  10. Acell, Inc. $11,992 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Xpert Xpress MVP Test $81,481 1 payment
  2. Xpress MVP $55,519 4 payments
  3. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus $52,360 2 payments
  4. A Single-Arm, Open-Label, Prospective, Observational Study to Assess the Safety of Sulbactam-Durlobactam, Including the Risk of Hypersensitivity Reactions (Including Anaphylaxis) in Participants With Acinetobacter Baumannii-Calcoaceticus Complex Infection $45,606 5 payments
  5. An open-label, multicenter, outpatient extension study to evaluate the safety and tolerability of Staccato alprazolam in STUDY participants 12 years of age and older with stereotypical prolonged seizures $33,341 1 payment
  6. Agili-C Post-Approval $32,679 1 payment
  7. Lutonix Av Pas Cl003301 $30,695 3 payments
  8. PH Iib of Astegolimab in COPD $25,302 8 payments
  9. Multicenter, Open-Label Trial to Evaluate the Safety and Tolerability of Intravenous Eravacycline in Children From 8 Years to Less Than 18 Years of Age With Complicated Intra-Abdominal Infections (Ciai) $22,467 6 payments
  10. A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection $19,539 1 payment
What the money was spent on Research payments · program years 2019–2025
  1. Medical research writing or publication $11,992 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record